Shares of Heat Biologics Inc. (Nasdaq: HTBX) continued to surge ahead of its Phase 1b study data presentation next week at the International Society for the Study of Lung Cancer Annual Meeting for its lung cancer treatment HS-110 in combination with Bristol-Myers Squibb's anti-PD-1 checkpoint inhibitor nivolumab. The stock price soared 74 cents to close at $3.23.
Heat Biologics soars
November 28, 2016 at 16:43 PM EST
